Literature DB >> 9544920

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.

M W Kline1, C V Fletcher, A T Harris, K D Evans, R C Brundage, R P Remmel, N R Calles, S B Kirkpatrick, C Simon.   

Abstract

Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9544920     DOI： 10.1016/s0022-3476(98)70039-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  14 in total

Review 1.  Indinavir: a review of its use in the management of HIV infection.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Didanosine: an updated review of its use in HIV infection.

Authors:  C M Perry; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.

Authors:  A S Bergshoeff; P L A Fraaij; A M C van Rossum; G Verweel; L H Wynne; G A Winchell; R Y Leavitt; B-Y T Nguyen; R de Groot; D M Burger
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 4.  Stavudine: an update of its use in the treatment of HIV infection.

Authors:  M Hurst; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

5.  Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children.

Authors:  Ram Yogev; Andrea Kovacs; Ellen G Chadwick; James D Homans; Yu Lou; William T Symonds
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

6.  Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.

Authors:  G Gatti; A Vigano'; N Sala; S Vella; M Bassetti; D Bassetti; N Principi
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 7.  Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries.

Authors:  Elizabeth Peacock-Villada; Barbra A Richardson; Grace C John-Stewart
Journal:  Pediatrics       Date:  2011-01-24       Impact factor: 7.124

Review 8.  The role of protease inhibitor therapy in children with HIV infection.

Authors:  Patrick J Gavin; Ram Yogev
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

9.  Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting.

Authors:  Kunjal Patel; Miguel A Hernán; Paige L Williams; John D Seeger; Kenneth McIntosh; Russell B Van Dyke; George R Seage
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

Review 10.  Triple nucleoside reverse transcriptase inhibitor therapy in children.

Authors:  Jennifer Handforth; Mike Sharland
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.